Biomarck Pharmaceuticals, has received the first three-quarters of a million in a $6 million equity raise, according to a filing with the U.S. Securities and Exchange Commission. BioMark is currently developing its lead compound, BIO-11006 for non small cell lung cancer (NSCLC) and acute respiratory distress syndrome (ARDS).
The company has raised $751,320 of the $6 million equity round from eight investors.
Co-discovered by Dr. Kenneth Adler, professor in North Carolina State University’s Department of Molecular Biomedical Sciences, who holds or co-holds 51 patents, the company’s peptide targets and inhibits the MARCKS protein. The protein is associated with respiratory disease and cancer.
BioMarck founder Dr. Linda D. Martin, then a biology professor at NCSU is co-discoverer of the “Marcks peptide.” She is not listed among the company’s officers in the SEC filing or on the company web page.
Brian Dickson, MD, is CEO of the company and Mike Enright is CFO. Indu Parikh, PhD is chief scientific officer.
Some press accounts call the BioMark peptide a “miracle drug.” It has performed well in animal tests and pre-clinical and clinical trials. Two phase 2 and a preclinical trial are scheduled for 2017.
Studies have shown fficacy in stopping metastases and reducing primary tumor size used alone and significantly increases the effectiveness of the platinum treatment cisplatin.
In animal models, it not only prevents development of ARDS, it can reverse it even when established.
Founded in 2002, the company raised more than $14 million in previous equity rounds, more than $200,000 in debt, and grants and awards.
SEC filing
